In:
PLOS ONE, Public Library of Science (PLoS), Vol. 16, No. 8 ( 2021-8-17), p. e0256352-
Abstract:
Rapid tests for SARS-COV-2 infection are important tools for pandemic control, but current rapid tests are based on proprietary designs and reagents. We report clinical validation results of an open-access lateral flow assay (OA-LFA) design using commercially available materials and reagents, along with RT-qPCR and commercially available comparators (BinaxNOW® and Sofia®). Adult patients with suspected COVID-19 based on clinical signs and symptoms, and with symptoms ≤7 days duration, underwent anterior nares (AN) sampling for the OA-LFA, Sofia®, BinaxNOW ™, and RT-qPCR, along with nasopharyngeal (NP) RT-qPCR. Results indicate a positive predictive agreement with NP sampling as 69% (60% -78%) OA-LFA, 74% (64% - 82%) Sofia®, and 82% (73% - 88%) BinaxNOW™. The implication for these results is that we provide an open-access LFA design that meets the minimum WHO target product profile for a rapid test, that virtually any diagnostic manufacturer could produce.
Type of Medium:
Online Resource
ISSN:
1932-6203
DOI:
10.1371/journal.pone.0256352
DOI:
10.1371/journal.pone.0256352.g001
DOI:
10.1371/journal.pone.0256352.g002
DOI:
10.1371/journal.pone.0256352.g003
DOI:
10.1371/journal.pone.0256352.g004
DOI:
10.1371/journal.pone.0256352.t001
DOI:
10.1371/journal.pone.0256352.t002
DOI:
10.1371/journal.pone.0256352.s001
DOI:
10.1371/journal.pone.0256352.s002
DOI:
10.1371/journal.pone.0256352.s003
DOI:
10.1371/journal.pone.0256352.s004
DOI:
10.1371/journal.pone.0256352.s005
DOI:
10.1371/journal.pone.0256352.s006
DOI:
10.1371/journal.pone.0256352.s007
DOI:
10.1371/journal.pone.0256352.s008
DOI:
10.1371/journal.pone.0256352.s009
DOI:
10.1371/journal.pone.0256352.r001
DOI:
10.1371/journal.pone.0256352.r002
DOI:
10.1371/journal.pone.0256352.r003
DOI:
10.1371/journal.pone.0256352.r004
Language:
English
Publisher:
Public Library of Science (PLoS)
Publication Date:
2021
detail.hit.zdb_id:
2267670-3
Permalink